Online inquiry

IVTScrip™ mRNA-Anti-CD40LG, BMS-986004(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4588MR)

This product GTTS-WQ4588MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CD40LG gene. The antibody can be applied in Inflammatory diseases research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000074.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 959
UniProt ID P29965
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD40LG, BMS-986004(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ4588MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13033MR IVTScrip™ mRNA-Anti-IFNAR, Peg-IFNA2 R23(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA Peg-IFNA2 R23
GTTS-WQ12854MR IVTScrip™ mRNA-Anti-TLR2, OPN-305(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA OPN-305
GTTS-WQ11850MR IVTScrip™ mRNA-Anti-TIGIT, MK-7684(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MK-7684
GTTS-WQ3796MR IVTScrip™ mRNA-Anti-Factor VIIa substitute, BAY-86-6150(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BAY-86-6150
GTTS-WQ645MR IVTScrip™ mRNA-Anti-AOC3, 8c10(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 8c10
GTTS-WQ5276MR IVTScrip™ mRNA-Anti-IL4-α, CD124(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CD124
GTTS-WQ5745MR IVTScrip™ mRNA-Anti-CEACAM5, CEA-IL-2v(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CEA-IL-2v
GTTS-WQ10617MR IVTScrip™ mRNA-Anti-PDCD1, LY3300054(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LY3300054
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW